Seragon Pharmaceuticals' Acquisition

Seragon Pharmaceuticals was acquired by Genentech on July 02, 2014.

Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform. Seragon Pharmaceuticals' orally active selective estrogen…

Articles about Seragon Pharmaceuticals' Acquisition: